Avitia Raises $5M Seed Funding to Expand AI-Powered Cancer Mutation Testing

Avitia’s AI/ML-powered platform transforms cancer diagnostics by bringing advanced testing directly to laboratories instead of relying on third-party facilities.

Avitia Raises $5M Seed Funding to Expand AI-Powered Cancer Mutation Testing
Source: Avitia

Company Name: Avitia
Location: Montreal, Canada
Industry: AI-Powered Cancer Testing & Precision Medicine

Funding Details:

  • Amount: $5M (Seed Round)
  • Investor: PacBridge Capital Partners

Purpose of Investment:

  • Expand into new markets to reach more healthcare providers.
  • Enhance AI/ML-powered platform to improve cancer mutation detection and treatment recommendations.

Leadership:

Product:

Avitia provides end-to-end AI-powered testing solutions designed to rapidly identify cancer mutations and applicable treatments. The company’s modular precision medicine technology enables cancer centers to conduct next-generation sequencing (NGS) testing on-site, reducing wait times and costs while improving patient outcomes.

Key features include:

  • AI-driven NGS-molecular testing solutions that deliver precise mutation analysis.
  • Automated liquid biopsy assays that eliminate the need for outsourcing.
  • Network-wide insights to improve treatment decisions across healthcare institutions.

About the Company:

Avitia’s AI/ML-powered platform transforms cancer diagnostics by bringing advanced testing directly to laboratories instead of relying on third-party facilities. This allows any lab to conduct liquid biopsy assays in-house, accelerating the detection of cancer mutations and streamlining treatment selection.

Current Customers & Market Presence:

  • Partners in Canada, the United States, and Southeast Asia currently use Avitia’s technology.

Future Plans:

With this funding, Avitia aims to scale its AI-powered cancer testing platform globally, further reduce testing costs, and improve access to rapid and accurate cancer diagnostics.

Read next